Biocytogen Pharmaceuticals (Beijing) Co (HKSE:02315) Price-to-Tangible-Book : 4.26 (As of May. 29, 2024)

View and export this data going back to 2022. Start your Free Trial

What is Biocytogen Pharmaceuticals (Beijing) Co Price-to-Tangible-Book?

As of today (2024-05-29), Biocytogen Pharmaceuticals (Beijing) Co's share price is HK$8.87. Biocytogen Pharmaceuticals (Beijing) Co's Tangible Book per Share of Dec. 2023 for the quarter that ended in Dec. 2023 was HK$2.08. Hence, Biocytogen Pharmaceuticals (Beijing) Co's Price to Tangible Book Ratio of today is 4.26.

The historical rank and industry rank for Biocytogen Pharmaceuticals (Beijing) Co's Price-to-Tangible-Book or its related term are showing as below:

HKSE:02315' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 4.26 Med: 6.99 Max: 8.22
Current: 4.26

During the past 4 years, Biocytogen Pharmaceuticals (Beijing) Co's highest Price to Tangible Book Ratio was 8.22. The lowest was 4.26. And the median was 6.99.

HKSE:02315's Price-to-Tangible-Book is ranked worse than
66.09% of 1218 companies
in the Biotechnology industry
Industry Median: 2.83 vs HKSE:02315: 4.26

A closely related ratio is called PB Ratio. As of today, Biocytogen Pharmaceuticals (Beijing) Co's share price is HK$8.87. Biocytogen Pharmaceuticals (Beijing) Co's Book Value per Sharefor the quarter that ended in Dec. 2023 was HK$2.16. Hence, Biocytogen Pharmaceuticals (Beijing) Co's P/B Ratio of today is 4.11.

Biocytogen Pharmaceuticals (Beijing) Co Price-to-Tangible-Book Historical Data

The historical data trend for Biocytogen Pharmaceuticals (Beijing) Co's Price-to-Tangible-Book can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biocytogen Pharmaceuticals (Beijing) Co Price-to-Tangible-Book Chart

Biocytogen Pharmaceuticals (Beijing) Co Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Price-to-Tangible-Book

8.22

5.76

Biocytogen Pharmaceuticals (Beijing) Co Semi-Annual Data
	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Price-to-Tangible-Book	Get a 7-Day Free Trial			-	-	8.22	8.26	5.76

Competitive Comparison of Biocytogen Pharmaceuticals (Beijing) Co's Price-to-Tangible-Book

For the Biotechnology subindustry, Biocytogen Pharmaceuticals (Beijing) Co's Price-to-Tangible-Book, along with its competitors' market caps and Price-to-Tangible-Book data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Biocytogen Pharmaceuticals (Beijing) Co's Price-to-Tangible-Book Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Biocytogen Pharmaceuticals (Beijing) Co's Price-to-Tangible-Book distribution charts can be found below:

* The bar in red indicates where Biocytogen Pharmaceuticals (Beijing) Co's Price-to-Tangible-Book falls into.

Biocytogen Pharmaceuticals (Beijing) Co Price-to-Tangible-Book Calculation

Biocytogen Pharmaceuticals (Beijing) Co's price-to-tangible-book ratio for today is calculated as:

Price to Tangible Book	=	Share Price	/	Tangible Book per Share (Q: Dec. 2023 )
	=	8.87	/	2.081
	=	4.26

It can also be calculated from the numbers for the whole company:

Price to Tangible Book	=	Market Cap	/	Tangible Equity
	=	Market Cap	/	(Total Stockholders Equity	-	Preferred Stock	-	Intangible Assets)

A closely related ratio is called PB Ratio. The difference between Price-to-Tangible-Book Ratio and PB Ratio is that book value other than intangibles are used in the calculation.

Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The Price-to-Book Ratio does not work well for these companies. Some companies even have negative equity, so the Price-to-Book Ratio cannot be applied to them.

Biocytogen Pharmaceuticals (Beijing) Co Price-to-Tangible-Book Related Terms

Thank you for viewing the detailed overview of Biocytogen Pharmaceuticals (Beijing) Co's Price-to-Tangible-Book provided by GuruFocus.com. Please click on the following links to see related term pages.

Biocytogen Pharmaceuticals (Beijing) Co (HKSE:02315) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Biocytogen Pharmaceuticals (Beijing) Co Ltd (HKSE:02315) » Definitions » Price-to-Tangible-Book

Comparable Companies

Traded in Other Exchanges

I54:Germany

Address

12 Baoshen South Street, Daxing Bio-Medicine Industry Park, Daxing District, Beijing, CHN

Website

https://www.biocytogen.com.cn

Biocytogen Pharmaceuticals (Beijing) Co Ltd is a biopharmaceutical and pre-clinical research services company. It has two Core Products, YH003 and YH001. YH003 is a recombinant humanized agonistic anti-Cluster of Differentiation 40 (CD40) Immunoglobulin G2 (IgG2) monoclonal antibody and YH001 is a recombinant humanized anti-CTLA-4, a protein receptor expressed constitutively on T cells that functions as an immune checkpoint and downregulates immune responses, Immunoglobulin G1 (IgG1) monoclonal antibody. YH003 is being developed for pancreatic ductal adenocarcinoma, melanoma and other advanced solid tumors. YH001 is being developed for hepatocellular carcinoma (HCC), non-small-cell lung carcinoma (NSCLC) and other solid tumors.

Executives

Bvcf Realization Fund, L.p.	2201 Interest of corporation controlled by you
Zhao Yin Guo Ji Jin Rong You Xian Gong Si	2201 Interest of corporation controlled by you
Zhao Yin Guo Ji Jin Rong Kong Gu You Xian Gong Si	2201 Interest of corporation controlled by you
Prowell Ventures Pte Ltd	2201 Interest of corporation controlled by you
Gic Special Investments Private Limited	2102 Investment manager
Gic Private Limited	2201 Interest of corporation controlled by you
Gic (ventures) Pte. Ltd.	2201 Interest of corporation controlled by you
Yang Zhi	2201 Interest of corporation controlled by you
Innoveda Medtech, Ltd.	2201 Interest of corporation controlled by you
Ni Jian
Bvcf Realization Fund Gp, Ltd.	2201 Interest of corporation controlled by you
Bioveda China Fund Ii Rmb, Limited	2101 Beneficial owner
Cmbi Private Equity Series Spc	2201 Interest of corporation controlled by you
Cmb International Private Investment Limited	2201 Interest of corporation controlled by you
Cmb International Investment Management Limited	2201 Interest of corporation controlled by you

Biocytogen Pharmaceuticals (Beijing) Co (HKSE:02315) Headlines

No Headlines